Related Experiment Video
Updated: May 6, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
BC-box protein domain-related mechanism for VHL protein degradation
Maria Elena Pozzebon1, Archana Varadaraj, Domenico Mattoscio
1Department of Experimental Oncology, European Institute of Oncology, 20139 Milan, Italy.
Insights
Viral protein Gam1 hijacks cellular machinery to degrade the tumor suppressor VHL (von Hippel-Lindau) protein. This process stabilizes hypoxia-inducible factor 1α, impacting gene expression.
Area of Science:
- Molecular Biology
- Virology
- Cancer Research
Background:
- The von Hippel-Lindau (VHL) protein acts as a substrate receptor for Cullin Ring Ligase (CRL) complexes, targeting hypoxia-inducible factor 1α (HIF-1α) for degradation.
- Adenoviral protein Gam1 utilizes a BC-box domain to interact with host Elongin B/C, functioning as a viral substrate receptor.
Purpose of the Study:
- To investigate the mechanism by which Gam1 induces VHL protein degradation.
- To characterize the role of CRL complexes in VHL protein turnover.
- To explore the impact of viral and cellular BC-box proteins on VHL stability.
Main Methods:
- Expression of viral proteins (Gam1) and cellular proteins with BC-box domains.
- Analysis of VHL protein degradation via proteasome.
- Assessment of hypoxia-inducible factor 1α stabilization and downstream target induction.
- Characterization of Cullin Ring Ligase (CRL) complex involvement.
Main Results:
- Gam1 expression leads to VHL protein degradation, consequently stabilizing hypoxia-inducible factor 1α and inducing its targets.
- A CRL-dependent mechanism drives VHL protein degradation through the proteasome.
- Viral and cellular BC-box proteins, including those with Suppressor of Cytokine Signaling (SOCS) domains, induce VHL degradation.
Conclusions:
- Viral proteins can hijack cellular pathways to regulate key host proteins like VHL.
- The interaction of viral BC-box proteins with host CRLs offers a novel mechanism for controlling cellular processes.
- Understanding these viral strategies provides insights into VHL regulation and potential therapeutic targets.
Abstract:
The tumor suppressor VHL (von Hippel-Lindau) protein is a substrate receptor for Ubiquitin Cullin Ring Ligase complexes (CRLs), containing a BC-box domain that associates to the adaptor Elongin B/C. VHL targets hypoxia-inducible factor 1α to proteasome-dependent degradation. Gam1 is an adenoviral protein, which also possesses a BC-box domain that interacts with the host Elongin B/C, thereby acting as a viral substrate receptor. Gam1 associates with both Cullin2 and Cullin5 to form CRL complexes targeting the host protein SUMO enzyme SAE1 for proteasomal degradation. We show that Gam1 protein expression induces VHL protein degradation leading to hypoxia-inducible factor 1α stabilization and induction of its downstream targets. We also characterize the CRL-dependent mechanism that drives VHL protein degradation via proteasome. Interestingly, expression of Suppressor of Cytokine Signaling (SOCS) domain-containing viral proteins and cellular BC-box proteins leads to VHL protein degradation, in a SOCS domain-containing manner. Our work underscores the exquisite ability of viral domains to uncover new regulatory mechanisms by hijacking key cellular proteins.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Anaphase Promoting Complex
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

